AbbVie: Migraine Disorders trials

The registry lists 52 Migraine Disorders studies with AbbVie as lead sponsor. 8 are open to participants now and 32 have results posted.

Phase 1 2Phase 2 4Phase 3 26Phase 4 5No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United KingdomNot yet recruitingNCT07690215
• Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine AttacksRecruitingNCT07310290
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingNCT06810505Phase 3
• Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic MigraineRecruitingNCT06603558
• A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineRecruitingNCT06602479Phase 2
• Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During PregnancyRecruitingNCT05158894
• Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)Enrolling by invitationNCT05127954Phase 3
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RecruitingNCT05125302Phase 3
• Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineCompletedNCT05861427Phase 3Results posted
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With MigraineCompletedNCT05748483Phase 3Results posted
• Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedNCT05264129Phase 4Results posted
• Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineCompletedNCT05216263Phase 3Results posted
• Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigraineTerminatedNCT05028569Phase 3Results posted
• Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedNCT04829747Phase 3Results posted
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedNCT04740827Phase 3Results posted
• Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult ParticipantsCompletedNCT04492020Phase 3Results posted
• Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineCompletedNCT04179474Phase 1Results posted
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03939312Phase 3Results posted
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineCompletedNCT03855137Phase 3Results posted
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigraineCompletedNCT03777059Phase 3Results posted
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03700320Phase 3Results posted
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of MigraineCompletedNCT02873221Phase 3Results posted
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of MigraineCompletedNCT02867709Phase 3Results posted
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine PreventionCompletedNCT02848326Phase 2/3Results posted
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of MigraineCompletedNCT02828020Phase 3Results posted
• Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in AdultsCompletedNCT02191579Phase 4Results posted
• A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic MigraineCompletedNCT02147561Phase 4Results posted
• A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and HeadacheCompletedNCT01946126Results posted
• Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)CompletedNCT01833130Phase 4Results posted
• A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic MigrainesCompletedNCT01749410Results posted
• An Observational Study of BOTOX® as Headache Prophylaxis for Chronic MigraineCompletedNCT01686581Results posted
• A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic MigraineCompletedNCT01662492Phase 3Results posted
• A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)CompletedNCT01657370Phase 2Results posted
• Chronic Migraine Epidemiology and Outcomes StudyCompletedNCT01648530Results posted
• A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)CompletedNCT01613248Phase 2Results posted
• A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic MigraineCompletedNCT01516892Phase 4Results posted
• BOTOX® Prophylaxis in Patients With Chronic MigraineCompletedNCT01432379Results posted
• Phase 3 Study of MAP0004 in Adult MigraineursCompletedNCT00623636Phase 3Results posted
• A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent HeadachesCompletedNCT00168428Phase 3Results posted
• A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent HeadachesCompletedNCT00156910Phase 3Results posted
• Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In CanadaCompletedNCT06692881
• Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineActive, not recruitingNCT06543914
• Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06417775Phase 3
• Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineCompletedNCT06241313Phase 3
• An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult ParticipantsCompletedNCT05827887
• An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult ParticipantsCompletedNCT05653986
• Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedNCT04818515Phase 1
• Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic MigraineWithdrawnNCT03193359Phase 3
• BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic MigraineWithdrawnNCT03193346Phase 3
• Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®CompletedNCT02502123
• Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in KoreaCompletedNCT01976611
• A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic MigrainesWithdrawnNCT01749423